.jpg?format=webp&quality=80&width=3840)
The study aimed to determine whether sulphonylurea monotherapy is associated with a higher risk of ventricular arrhythmia (VA) compared to metformin monotherapy among patients initiating pharmacotherapy for type 2 diabetes. A population-based cohort study was conducted using electronic health data from the UK's Clinical Practice Research Datalink Aurum. The results showed that sulphonylureas were associated with an increased risk of VA when used as first-line therapy for type 2 diabetes compared to metformin. This increased risk should be considered when prescribing sulphonylureas as an initial treatment for type 2 diabetes.
Like
Save
Share